Hims & Hers to offer peptides as soon as November after US eases curbs

What happened

Hims & Hers Health said it will begin selling glutathione, sermorelin and NAD+ wellness products in November after US regulators eased restrictions on compounding certain unapproved peptides. The company said it plans to offer BPC-157 and TB-500 later, and its CEO said Hims would manufacture those two peptides in the United States.

Confirmed

Global impact / market context

The change gives Hims a route to sell products sought by fitness and longevity customers, potentially adding revenue. But enforcement discretion is not FDA approval, so safety concerns or later regulatory action could limit sales, raise compliance costs, or weaken customer demand.

Analyst inference

The article describes growing interest in peptides while noting that the products have not been assessed by the FDA for safety and effectiveness. For investors, this creates a tension between potential wellness-product demand and regulatory uncertainty that may affect Hims’ costs and sales.

Analyst inference

What to watch

1. Check whether the November launch includes all three announced products and whether Hims reports customer demand or revenue from them in later company updates. Analyst inference
2. Watch for further government guidance on compounding BPC-157 and TB-500, since the company said these products would come later and the policy is not FDA approval. Confirmed
3. Look for any FDA safety or effectiveness assessment, because these products have not been assessed and new findings could change demand or selling restrictions. Analyst inference

Evidence

• Original source link unavailable